ERRATUM Open Access



Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study


Lisa Rosenblatt¹, Amanda M. Farr^{2*}, Ella T. Nkhoma³, James K. Nelson⁴, Corey Ritchings⁵ and Stephen S. Johnston⁶

Erratum

n.b. The errors and associated corrections described in this document concerning the original manuscript were accountable to the production department handling this manuscript, and thus are no fault of the authors of this paper. Additionally, the online manuscript has now been updated with these corrections accordingly.

In the original publication of this article [1], Fig. 3 had [VALUE] (0.72, 2.23) where it should have said 1.27 (0.72, 2.23). This has now been updated in the original article.

²Truven Health Analytics, 150 Cambridgepark Drive, Cambridge, MA 02140,





^{*} Correspondence: amanda.farr@truvenhealth.com




Fig. 3 Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. *CI* confidence interval, *CV* cardiovascular, *DRV* darunavir, *HR* hazard ratio, *PI* protease inhibitor

Author details

¹Bristol-Myers Squibb, 777 Scudders Mill Road, Plainsboro, NJ 08536, USA.
²Truven Health Analytics, 150 Cambridgepark Drive, Cambridge, MA 02140, USA.
³Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA.
⁴Truven Health Analytics, 100 Phoenix Drive, Ann Arbor, MI 48108, USA.
⁵Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08540, USA.
⁶Truven Health Analytics, 7700 Old Georgetown Road, Bethesda, MD 20814, USA.

Received: 27 September 2016 Accepted: 5 October 2016 Published online: 07 October 2016

References

 Rosenblatt L, et al. Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study. BMC Infect Dis. 2016;16:492. doi:10.1186/s12879-016-1827-1.